(0)サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1702264

不眠症の市場規模、シェア、動向、予測：治療タイプ、薬剤クラス別、流通チャネル、地域別、2025年～2033年

Insomnia Market Size, Share, Trends and Forecast by Therapy Type, Drug Class, Distribution Channel, and Region, 2025-2033

出版日
発行
IMARC
ページ情報
英文 150 Pages
納期
2～3営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=146.35円
不眠症の市場規模、シェア、動向、予測：治療タイプ、薬剤クラス別、流通チャネル、地域別、2025年～2033年
出版日: 2025年04月01日
発行: IMARC
ページ情報: 英文 150 Pages
納期: 2～3営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

不眠症の世界市場規模は2024年に53億4,000万米ドルとなりました。今後、IMARC Groupは、市場は2033年までに67億8,000万米ドルに達し、2025年から2033年にかけて2.55％のCAGRを示すと予測しています。現在、北米が市場を独占しており、2024年には36.4%を超える大きな市場シェアを占めています。現代的なライフスタイルやストレスによるヘルスケアの調査増加、診断技術の進歩による精度の向上、新規治療法の有力な研究、医療費の増加、デジタルヘルスソリューションの統合、戦略的な業界提携、非薬物療法に対する消費者の嗜好の高まりなどが、市場成長を後押しする要因となっています。これに加えて、先進ヘルスケア、睡眠障害の高い有病率、革新的な治療の採用が、不眠症の市場のシェアをさらに高めています。

不眠症は、エネルギーレベルを低下させ、個人の気分、健康、仕事のパフォーマンス、全体的な生活の質に影響を与える睡眠障害です。一般的な原因としては、ストレス、長期の旅行、多忙な仕事スケジュール、睡眠習慣の乱れ、暴飲暴食、ニコチン、カフェイン、アルコールの過剰摂取などが挙げられます。また、心的外傷後ストレスなどの精神疾患や、喘息や血圧のための抗うつ薬、鎮痛・アレルギー・風邪のための一般用医薬品（OTC）などの薬剤の使用とも関連することがあります。認知行動療法（CBT）、OTC睡眠補助薬、エスゾピクロンやラメルテオンのような処方薬など、その治療選択肢は現在世界中で利用可能です。

不眠症の市場動向：

コロナウイルス感染症（COVID-19）の大流行は、社会的孤立、無数の仕事上の課題、家族の義務など、生活に前例のない変化をもたらしました。これは数百万人の睡眠パターンに影響を与える大きなストレスとなり、市場の成長を強めました。さらに、慢性疼痛、がん、糖尿病、心臓病、喘息、胃食道逆流症（GERD）、活動し過ぎの甲状腺、パーキンソン病、アルツハイマー病などの病状は、通常、不眠症と関連しています。したがって、これらの病気に苦しむ人の増加が、不眠症治療薬の需要を押し上げています。これとは別に、月経周期や更年期におけるホルモンの変化は、不眠症の発症リスクにつながる可能性があり、これが市場の成長に寄与しています。さらに、睡眠パターン、活動、健康の変化や処方薬の使用増加により、高齢者の不眠症の可能性が高まるため、世界の老人人口の増加が不眠症治療に対する需要を刺激しています。さらに、不眠症を予防、検出、治療、管理するための新しい治療、介入、検査の試験への投資の増加が市場を牽引すると予想されています。

本レポートで扱う主な質問

  • 不眠症の市場の市場規模は？
  • 不眠症の市場の将来展望は？
  • 不眠症の市場を牽引する主な要因は何か？
  • 不眠症の市場のシェアが最も高い地域はどこか？
  • 世界の不眠症の市場の主要企業は？

目次

第1章 序文

第2章 調査範囲と調査手法

  • 調査の目的
  • ステークホルダー
  • データソース
    • 一次情報
    • 二次情報
  • 市場推定
    • ボトムアップアプローチ
    • トップダウンアプローチ
  • 調査手法

第3章 エグゼクティブサマリー

第4章 イントロダクション

  • 概要
  • 主要業界動向

第5章 世界の不眠症市場

  • 市場概要
  • 市場実績
  • COVID-19の影響
  • 市場予測

第6章 市場内訳：治療タイプ別

  • 非薬物療法
    • 主要セグメント
      • 催眠療法
      • 認知行動療法
      • 医療機器
      • その他
  • 薬物療法
    • 主要セグメント
      • 処方睡眠補助薬
      • OTC睡眠補助薬

第7章 市場内訳：薬剤クラス別

  • 抗うつ薬
  • メラトニン拮抗薬
  • ベンゾジアゼピン
  • 非ベンゾジアゼピン系薬剤
  • オレキシン拮抗薬
  • その他

第8章 市場内訳：流通チャネル別

  • 病院薬局
  • 小売薬局
  • ドラッグストア
  • オンライン薬局

第9章 市場内訳：地域別

  • 北米
    • 米国
    • カナダ
  • アジア太平洋地域
    • 中国
    • 日本
    • インド
    • 韓国
    • オーストラリア
    • インドネシア
    • その他
  • 欧州
    • ドイツ
    • フランス
    • 英国
    • イタリア
    • スペイン
    • ロシア
    • その他
  • ラテンアメリカ
    • ブラジル
    • メキシコ
    • その他
  • 中東・アフリカ
    • 市場内訳：国別

第10章 SWOT分析

  • 概要
  • 強み
  • 弱み
  • 機会
  • 脅威

第11章 バリューチェーン分析

第12章 ポーターのファイブフォース分析

  • 概要
  • 買い手の交渉力
  • 供給企業の交渉力
  • 競合の程度
  • 新規参入業者の脅威
  • 代替品の脅威

第13章 価格分析

第14章 競合情勢

  • 市場構造
  • 主要企業
  • 主要企業のプロファイル
    • Astellas Pharma Inc.
    • Aurobindo Pharma Limited
    • Biocodex
    • Eisai Co. Ltd.
    • Mallinckrodt Pharmaceuticals
    • Merck & Co. Inc.
    • Neurim Pharmaceuticals Inc.
    • Pfizer Inc.
    • Sanofi S.A.
    • Sumitomo Dainippon Pharma Co. Ltd.（Sumitomo Chemical Co. Ltd.）
    • Takeda Pharmaceutical Company Limited
    • Vanda Pharmaceuticals Inc.
図表

List of Figures

  • Figure 1: Global: Insomnia Market: Major Drivers and Challenges
  • Figure 2: Global: Insomnia Market: Sales Value (in Billion USD), 2019-2024
  • Figure 3: Global: Insomnia Market Forecast: Sales Value (in Billion USD), 2025-2033
  • Figure 4: Global: Insomnia Market: Breakup by Therapy Type (in %), 2024
  • Figure 5: Global: Insomnia Market: Breakup by Drug Class (in %), 2024
  • Figure 6: Global: Insomnia Market: Breakup by Distribution Channel (in %), 2024
  • Figure 7: Global: Insomnia Market: Breakup by Region (in %), 2024
  • Figure 8: Global: Insomnia (Non-Pharmacological Therapy) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 9: Global: Insomnia (Non-Pharmacological Therapy) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 10: Global: Insomnia (Pharmacological Therapy) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 11: Global: Insomnia (Pharmacological Therapy) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 12: Global: Insomnia (Antidepressants) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 13: Global: Insomnia (Antidepressants) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 14: Global: Insomnia (Melatonin Antagonist) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 15: Global: Insomnia (Melatonin Antagonist) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 16: Global: Insomnia (Benzodiazepines) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 17: Global: Insomnia (Benzodiazepines) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 18: Global: Insomnia (Nonbenzodiazepines) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 19: Global: Insomnia (Nonbenzodiazepines) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 20: Global: Insomnia (Orexin Antagonist) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 21: Global: Insomnia (Orexin Antagonist) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 22: Global: Insomnia (Other Drug Classes) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 23: Global: Insomnia (Other Drug Classes) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 24: Global: Insomnia (Hospital Pharmacies) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 25: Global: Insomnia (Hospital Pharmacies) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 26: Global: Insomnia (Retail Pharmacies) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 27: Global: Insomnia (Retail Pharmacies) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 28: Global: Insomnia (Drug Stores) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 29: Global: Insomnia (Drug Stores) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 30: Global: Insomnia (Online Pharmacies) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 31: Global: Insomnia (Online Pharmacies) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 32: North America: Insomnia Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 33: North America: Insomnia Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 34: United States: Insomnia Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 35: United States: Insomnia Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 36: Canada: Insomnia Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 37: Canada: Insomnia Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 38: Asia-Pacific: Insomnia Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 39: Asia-Pacific: Insomnia Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 40: China: Insomnia Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 41: China: Insomnia Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 42: Japan: Insomnia Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 43: Japan: Insomnia Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 44: India: Insomnia Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 45: India: Insomnia Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 46: South Korea: Insomnia Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 47: South Korea: Insomnia Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 48: Australia: Insomnia Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 49: Australia: Insomnia Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 50: Indonesia: Insomnia Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 51: Indonesia: Insomnia Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 52: Others: Insomnia Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 53: Others: Insomnia Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 54: Europe: Insomnia Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 55: Europe: Insomnia Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 56: Germany: Insomnia Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 57: Germany: Insomnia Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 58: France: Insomnia Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 59: France: Insomnia Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 60: United Kingdom: Insomnia Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 61: United Kingdom: Insomnia Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 62: Italy: Insomnia Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 63: Italy: Insomnia Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 64: Spain: Insomnia Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 65: Spain: Insomnia Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 66: Russia: Insomnia Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 67: Russia: Insomnia Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 68: Others: Insomnia Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 69: Others: Insomnia Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 70: Latin America: Insomnia Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 71: Latin America: Insomnia Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 72: Brazil: Insomnia Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 73: Brazil: Insomnia Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 74: Mexico: Insomnia Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 75: Mexico: Insomnia Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 76: Others: Insomnia Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 77: Others: Insomnia Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 78: Middle East and Africa: Insomnia Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 79: Middle East and Africa: Insomnia Market: Breakup by Country (in %), 2024
  • Figure 80: Middle East and Africa: Insomnia Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 81: Global: Insomnia Industry: SWOT Analysis
  • Figure 82: Global: Insomnia Industry: Value Chain Analysis
  • Figure 83: Global: Insomnia Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Insomnia Market: Key Industry Highlights, 2024 and 2033
  • Table 2: Global: Insomnia Market Forecast: Breakup by Therapy Type (in Million USD), 2025-2033
  • Table 3: Global: Insomnia Market Forecast: Breakup by Drug Class (in Million USD), 2025-2033
  • Table 4: Global: Insomnia Market Forecast: Breakup by Distribution Channel (in Million USD), 2025-2033
  • Table 5: Global: Insomnia Market Forecast: Breakup by Region (in Million USD), 2025-2033
  • Table 6: Global: Insomnia Market: Competitive Structure
  • Table 7: Global: Insomnia Market: Key Players
目次
Product Code: SR112025A6148

The global insomnia market size was valued at USD 5.34 Billion in 2024. Looking forward, IMARC Group estimates the market to reach USD 6.78 Billion by 2033, exhibiting a CAGR of 2.55% during 2025-2033. North America currently dominates the market, holding a significant market share of over 36.4% in 2024. Increasing prevalence due to modern lifestyles and stress, advancements in diagnostic technologies enhancing accuracy, robust research into novel therapies, rising healthcare expenditures, integration of digital health solutions, strategic industry collaborations, and growing consumer preference for non-pharmacological treatments are some of the factors bolstering the market growth. In addition to this, advanced healthcare, high sleep disorder prevalence, and adoption of innovative treatments are further increasing the insomnia market share.

Insomnia is a sleep disorder that can lower energy levels and affect the mood, health, work performance, and overall life quality of an individual. Its common causes include stress, long travels, hectic work schedules, poor sleep habits, binge eating, and excessive consumption of nicotine, caffeine, and alcohol. It can also be associated with mental health disorders, such as post-traumatic stress, and the use of drugs like antidepressants for asthma or blood pressure and over-the-counter (OTC) for pain relief, allergy, and cold. Its treatment options, such as cognitive-behavioral therapy (CBT), OTC sleep aids, and prescription medications like Eszopiclone and Ramelteon, are currently available worldwide.

Insomnia Market Trends:

The coronavirus disease (COVID-19) pandemic generated unprecedented changes in lives, including social isolation and innumerable work challenges and family obligations. This acts as a major stressful event that impacted the sleep patterns of millions and strengthened the market growth. Moreover, medical conditions, such as chronic pain, cancer, diabetes, heart disease, asthma, gastroesophageal reflux disease (GERD), overactive thyroid, Parkinson's disease, and Alzheimer's disease, are usually linked with insomnia. Hence, the increasing number of individuals suffering from these ailments is driving the demand for insomnia medications. Apart from this, hormonal shifts during the menstrual cycle and menopause can lead to the risk of developing insomnia, which is contributing to the market growth. In addition, as changes in sleep patterns, activity, and health and the rising use of prescription drugs can increase the chance of insomnia among older people, the growing geriatric population globally is catalyzing the demand for insomnia medical treatment. Furthermore, increasing investments in testing new treatments, interventions, and tests to prevent, detect, treat, and manage insomnia are anticipated to drive the market.

Key Market Segmentation:

Breakup by Therapy Type:

  • Non-Pharmacological Therapy
  • Hypnotherapy
  • Cognitive Behavioral Therapy
  • Medical Devices
  • Others
  • Pharmacological Therapy
  • Prescription Sleep Aids
  • Over-The-Counter Sleep Aids

Breakup by Drug Class:

  • Antidepressants
  • Melatonin Antagonist
  • Benzodiazepines
  • Nonbenzodiazepines
  • Orexin Antagonist
  • Others

Breakup by Distribution Channel:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Drug Stores
  • Online Pharmacies

Breakup by Region:

  • North America
  • United States
  • Canada
  • Asia-Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Indonesia
  • Others
  • Europe
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Russia
  • Others
  • Latin America
  • Brazil
  • Mexico
  • Others
  • Middle East and Africa

Competitive Landscape:

The competitive landscape of the industry has also been examined along with the profiles of the key players being Astellas Pharma Inc., Aurobindo Pharma Limited, Biocodex, Eisai Co. Ltd., Mallinckrodt Pharmaceuticals, Merck & Co. Inc., Neurim Pharmaceuticals Inc., Pfizer Inc., Sanofi S.A., Sumitomo Dainippon Pharma Co. Ltd. (Sumitomo Chemical Co. Ltd.), Takeda Pharmaceutical Company Limited and Vanda Pharmaceuticals Inc.

Key Questions Answered in This Report

  • 1.How big is the insomnia market?
  • 2.What is the future outlook of insomnia market?
  • 3.What are the key factors driving the insomnia market?
  • 4.Which region accounts for the largest insomnia market share?
  • 5.Which are the leading companies in the global insomnia market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Insomnia Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Therapy Type

  • 6.1 Non-Pharmacological Therapy
    • 6.1.1 Market Trends
    • 6.1.2 Key Segments
      • 6.1.2.1 Hypnotherapy
      • 6.1.2.2 Cognitive Behavioral Therapy
      • 6.1.2.3 Medical Devices
      • 6.1.2.4 Others
    • 6.1.3 Market Forecast
  • 6.2 Pharmacological Therapy
    • 6.2.1 Market Trends
    • 6.2.2 Key Segments
      • 6.2.2.1 Prescription Sleep Aids
      • 6.2.2.2 Over-The-Counter Sleep Aids
    • 6.2.3 Market Forecast

7 Market Breakup by Drug Class

  • 7.1 Antidepressants
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Melatonin Antagonist
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 Benzodiazepines
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast
  • 7.4 Nonbenzodiazepines
    • 7.4.1 Market Trends
    • 7.4.2 Market Forecast
  • 7.5 Orexin Antagonist
    • 7.5.1 Market Trends
    • 7.5.2 Market Forecast
  • 7.6 Others
    • 7.6.1 Market Trends
    • 7.6.2 Market Forecast

8 Market Breakup by Distribution Channel

  • 8.1 Hospital Pharmacies
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Retail Pharmacies
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Drug Stores
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast
  • 8.4 Online Pharmacies
    • 8.4.1 Market Trends
    • 8.4.2 Market Forecast

9 Market Breakup by Region

  • 9.1 North America
    • 9.1.1 United States
      • 9.1.1.1 Market Trends
      • 9.1.1.2 Market Forecast
    • 9.1.2 Canada
      • 9.1.2.1 Market Trends
      • 9.1.2.2 Market Forecast
  • 9.2 Asia-Pacific
    • 9.2.1 China
      • 9.2.1.1 Market Trends
      • 9.2.1.2 Market Forecast
    • 9.2.2 Japan
      • 9.2.2.1 Market Trends
      • 9.2.2.2 Market Forecast
    • 9.2.3 India
      • 9.2.3.1 Market Trends
      • 9.2.3.2 Market Forecast
    • 9.2.4 South Korea
      • 9.2.4.1 Market Trends
      • 9.2.4.2 Market Forecast
    • 9.2.5 Australia
      • 9.2.5.1 Market Trends
      • 9.2.5.2 Market Forecast
    • 9.2.6 Indonesia
      • 9.2.6.1 Market Trends
      • 9.2.6.2 Market Forecast
    • 9.2.7 Others
      • 9.2.7.1 Market Trends
      • 9.2.7.2 Market Forecast
  • 9.3 Europe
    • 9.3.1 Germany
      • 9.3.1.1 Market Trends
      • 9.3.1.2 Market Forecast
    • 9.3.2 France
      • 9.3.2.1 Market Trends
      • 9.3.2.2 Market Forecast
    • 9.3.3 United Kingdom
      • 9.3.3.1 Market Trends
      • 9.3.3.2 Market Forecast
    • 9.3.4 Italy
      • 9.3.4.1 Market Trends
      • 9.3.4.2 Market Forecast
    • 9.3.5 Spain
      • 9.3.5.1 Market Trends
      • 9.3.5.2 Market Forecast
    • 9.3.6 Russia
      • 9.3.6.1 Market Trends
      • 9.3.6.2 Market Forecast
    • 9.3.7 Others
      • 9.3.7.1 Market Trends
      • 9.3.7.2 Market Forecast
  • 9.4 Latin America
    • 9.4.1 Brazil
      • 9.4.1.1 Market Trends
      • 9.4.1.2 Market Forecast
    • 9.4.2 Mexico
      • 9.4.2.1 Market Trends
      • 9.4.2.2 Market Forecast
    • 9.4.3 Others
      • 9.4.3.1 Market Trends
      • 9.4.3.2 Market Forecast
  • 9.5 Middle East and Africa
    • 9.5.1 Market Trends
    • 9.5.2 Market Breakup by Country
    • 9.5.3 Market Forecast

10 SWOT Analysis

  • 10.1 Overview
  • 10.2 Strengths
  • 10.3 Weaknesses
  • 10.4 Opportunities
  • 10.5 Threats

11 Value Chain Analysis

12 Porters Five Forces Analysis

  • 12.1 Overview
  • 12.2 Bargaining Power of Buyers
  • 12.3 Bargaining Power of Suppliers
  • 12.4 Degree of Competition
  • 12.5 Threat of New Entrants
  • 12.6 Threat of Substitutes

13 Price Analysis

14 Competitive Landscape

  • 14.1 Market Structure
  • 14.2 Key Players
  • 14.3 Profiles of Key Players
    • 14.3.1 Astellas Pharma Inc.
      • 14.3.1.1 Company Overview
      • 14.3.1.2 Product Portfolio
      • 14.3.1.3 Financials
      • 14.3.1.4 SWOT Analysis
    • 14.3.2 Aurobindo Pharma Limited
      • 14.3.2.1 Company Overview
      • 14.3.2.2 Product Portfolio
      • 14.3.2.3 Financials
    • 14.3.3 Biocodex
      • 14.3.3.1 Company Overview
      • 14.3.3.2 Product Portfolio
    • 14.3.4 Eisai Co. Ltd.
      • 14.3.4.1 Company Overview
      • 14.3.4.2 Product Portfolio
      • 14.3.4.3 Financials
      • 14.3.4.4 SWOT Analysis
    • 14.3.5 Mallinckrodt Pharmaceuticals
      • 14.3.5.1 Company Overview
      • 14.3.5.2 Product Portfolio
      • 14.3.5.3 Financials
    • 14.3.6 Merck & Co. Inc.
      • 14.3.6.1 Company Overview
      • 14.3.6.2 Product Portfolio
      • 14.3.6.3 Financials
      • 14.3.6.4 SWOT Analysis
    • 14.3.7 Neurim Pharmaceuticals Inc.
      • 14.3.7.1 Company Overview
      • 14.3.7.2 Product Portfolio
    • 14.3.8 Pfizer Inc.
      • 14.3.8.1 Company Overview
      • 14.3.8.2 Product Portfolio
      • 14.3.8.3 Financials
      • 14.3.8.4 SWOT Analysis
    • 14.3.9 Sanofi S.A.
      • 14.3.9.1 Company Overview
      • 14.3.9.2 Product Portfolio
      • 14.3.9.3 Financials
      • 14.3.9.4 SWOT Analysis
    • 14.3.10 Sumitomo Dainippon Pharma Co. Ltd. (Sumitomo Chemical Co. Ltd.)
      • 14.3.10.1 Company Overview
      • 14.3.10.2 Product Portfolio
      • 14.3.10.3 Financials
      • 14.3.10.4 SWOT Analysis
    • 14.3.11 Takeda Pharmaceutical Company Limited
      • 14.3.11.1 Company Overview
      • 14.3.11.2 Product Portfolio
      • 14.3.11.3 Financials
      • 14.3.11.4 SWOT Analysis
    • 14.3.12 Vanda Pharmaceuticals Inc.
      • 14.3.12.1 Company Overview
      • 14.3.12.2 Product Portfolio
      • 14.3.12.3 Financials